四環醫藥:2023年度報告
Sihuan Pharmaceutical (00460.HK): Three Mendon insulin series products developed by Huisheng Biotech have obtained the proposed selection criteria in the special continuous procurement of insulin
Gelonghui, April 25, 丨 Sihuan Pharmaceutical (00460.HK) announced that on April 23, 2024, Huisheng Biopharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the Group, participated in the national centralized drug procurement (insulin special continuation) declaration work organized by the State Organization Drug Joint Procurement Office. The three products developed by Huisheng Biotech, Mendon Insulin 30 Injection, and Menton Insulin 50 Injection were eligible for selection in this special succession of insulin purchases, and they all plan to select Class A varieties. The current centralized insulin procurement cycle starts from the date of implementation of the selection results to 2027
Sihuan Pharmaceutical (0460.HK): Two-wheel drive for medical aesthetics and innovative pharmaceuticals, “high valuation flexibility+high growth new business” creates the company's alpha
Against the backdrop of a weak economic environment in 2023, the medical and aesthetic industry showed a strong growth momentum. The latest financial data from the Hong Kong stock Sihuan Pharmaceutical also confirms this. In 2023, Sihuan Pharmaceutical's medical and aesthetic business revenue both achieved high growth, with revenue of 450 million yuan, up 200% year on year, and segment profit of 90 million yuan, up 2450% year on year.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460.HK) rose more than 5% in 23 years, and the company's medical and aesthetic earnings increased dramatically. Institutions believe that there is still a lot of room for improvement in China's medica
Sihuan Pharmaceutical (00460.HK) rose more than 5% and rose 5.77% at press time to HK$0.55, with a turnover of HK$2.94 million.
Sihuan Pharmaceutical (00460): Strong medical and aesthetic performance explodes, profit inflection point upward, leveraging valuation logic
Sihuan Pharmaceutical's dual growth logic continues to be interpreted.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical (HKG:0460) narrowed its 2023 loss attributable to owners to 54.0 million yuan, or 0.0058 yuan per share, from 1.91 billion yuan, from 0.2090 yuan per share, the previous year. Th
Sihuan Pharmaceutical (00460) announced its 2023 annual results, with total revenue reaching 1,860.5 billion yuan. The revenue of the medical and aesthetic division increased by about 200.3% year-on-year
According to Zhitong Finance App News, Sihuan Pharmaceutical (00460) released its annual results for the year ended December 31, 2023, with total revenue of approximately RMB 1,8605 million; of these, revenue from medical and aesthetic products was RMB 449.9 billion, up about 200.3% year on year, mainly due to the full liberalization of domestic epidemic control and the gradual recovery of consumer demand, the Group's medical and aesthetic platform Qianyan Space achieved phased success through channel inventory cleaning, strategic cooperation with many medical and aesthetic institutions, and vigorously promoted the 3.0 version upgrade of the marketing strategy. Successfully achieved medical and aesthetic sales revenue
SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings (HKG:0460) received a class III medical device registration certificate for Sylfirm X from the National Medical Products Administration of China, according to a filing w
Sylfirm X, a dual-wave radiofrequency therapy device exclusively represented by Sihuan Pharmaceutical (00460.HK), was issued a registration certificate for three types of medical devices by the State Drug Administration
GLONGHUI March 25 丨 Sihuan Pharmaceutical (00460.HK) announced that it is the exclusive agent of the Group and is managed by Korea's Vio Co., Ltd. (Viol.co. , Ltd.) The dual-wave radiofrequency therapy device Sylfirm X (the “Product”) manufactured by (“Vio Korea”) officially obtained a Class III medical device registration certificate issued by China's State Drug Administration on March 19, 2024. Sylfirm X is the world's first dual-wave radiofrequency treatment device approved by the US Food and Drug Administration (FDA) and the National Drug Administration. It emits high-frequency electric current to promote skin tissue coagulation, which can effectively reduce skin wrinkles
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Sihuan Pharmaceutical (00460.HK) plans to hold a board meeting on March 28 to approve the annual results
GLONGHUI March 18 | Sihuan Pharmaceutical (00460.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to approve (among other things) the results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider paying a final dividend (if any).
四環醫藥:董事會會議通知
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”
No Data